Lipocine Inc. Files 8-K for Material Agreements

Ticker: LPCN · Form: 8-K · Filed: 2024-10-23T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, corporate-action, filing

TL;DR

Lipocine Inc. filed an 8-K on Oct 22, 2024, detailing material agreements and changes to security holder rights.

AI Summary

On October 22, 2024, Lipocine Inc. entered into a material definitive agreement. The company also made modifications to the rights of its security holders and amended its articles of incorporation or bylaws. This filing also includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions by Lipocine Inc., including new agreements and potential changes affecting shareholder rights, which could impact the company's future operations and stock value.

Risk Assessment

Risk Level: medium — Material definitive agreements and modifications to security holder rights can introduce new risks or alter existing ones for investors.

Key Players & Entities

FAQ

What specific material definitive agreement did Lipocine Inc. enter into on October 22, 2024?

The filing indicates the entry into a material definitive agreement but does not specify its nature or terms within the provided text.

What are the key modifications to the rights of security holders mentioned in the filing?

The filing states that there were material modifications to the rights of security holders, but the specific details of these modifications are not provided in the excerpt.

What amendments were made to Lipocine Inc.'s articles of incorporation or bylaws?

The filing notes amendments to the articles of incorporation or bylaws, but the specific changes are not detailed in the provided text.

What is the Commission File Number for Lipocine Inc.'s 8-K filing?

The Commission File Number for Lipocine Inc. is 001-36357.

When is Lipocine Inc.'s fiscal year end?

Lipocine Inc.'s fiscal year ends on December 31.

From the Filing

0001493152-24-042117.txt : 20241023 0001493152-24-042117.hdr.sgml : 20241023 20241022183816 ACCESSION NUMBER: 0001493152-24-042117 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241022 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241023 DATE AS OF CHANGE: 20241022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241387465 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false --12-31 0001535955 0001535955 2024-10-22 2024-10-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): October 22, 2024     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 1.01 Entry into a Material Definitive Agreement.   On November 12, 2015, the Board of Directors of Lipocine Inc. (the “Company”) adopted a stockholder rights plan. The plan is similar to plans adopted by many other companies and was not adopted in response to any hostile takeover attempt. On November 5, 2018, the Board of

View on Read The Filing